levocetirizine dihydrochloride tablet, film coated
teva pharmaceuticals usa, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride tablets is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)] . patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by the ora
levocetirizine dihydrochloride tablet, film coated
aidarex pharmaceuticals llc - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. pediatric use information in pediatric patients (age 6 months to 5 years) is approved for ucb inc.’s levocetirizine dihydrochloride drug product labeling. however, due to ucb inc.’s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. the use of levocetirizine dihydrochloride tablet is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablet, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function pregnancy category b there are no adequate and well-controlled studies i
levocetirizine dihydrochloride tablet, film coated
dispensing solutions, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. pediatric use information in pediatric patients (age 6 months to 5 years) is approved for ucb inc.'s levocetirizine dihydrochloride drug product labeling. however, due to ucb inc.'s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. the use of levocetirizine dihydrochloride tablets is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions ( 6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. pregnancy category b there are no adequate and well-controlled studies in preg
montey l film-coated tablet
finecure pharmaceuticals ltd village shimla pistaur, malsa rd kichha udha m - montelukast sodium and levocetirizine - film-coated tablet - montelukast 10mg and levocetirizine 5mg - montelukast combinations
xyzal 5mg film coated tablet
glaxosmithkline pharmaceutical sdn. bhd. - levocetirizine dihydrochloride -
levocetirizine krka 5mg film-coated tablets
krka pharma dublin limited - levocetirizine dihydrochloride - film coated tablet - 5 milligram
levocetirizine dihydrochloride tablet, film coated
bryant ranch prepack - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by the oral r
stadeltine film-coated tablet 5mg
stadpharm sdn. bhd. - levocetirizine dihydrochloride -
alerinit film-coated tablet
İlko İlaç san. ve tic. a.Ş. veysel karani mah. Çolakoğlu sk. no:10 34885 - levocetirizine dihydrochloride - film-coated tablet - 5 mg levocetirizine dihydrochloride - antihistamines for systemic use: piperazine
xyzal film coated tablet 5 milligram
g & a licensing limited - levocetirizine dihydrochloride - film coated tablet - 5 milligram